Theravance Biopharma
TBPH
90 hedge funds and large institutions have $1.16B invested in Theravance Biopharma in 2018 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 33 increasing their positions, 26 reducing their positions, and 7 closing their positions.
596% more call options, than puts
Call options by funds: $2.66M | Put options by funds: $383K
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
27% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 26
7% more funds holding
Funds holding: 84 → 90 (+6)
0.31% more ownership
Funds ownership: 86.74% → 87.05% (+0.31%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
12% less capital invested
Capital invested by funds: $1.31B → $1.16B (-$152M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$11M |
| 2 |
LCM
Laurion Capital Management
New York
|
+$7.72M |
| 3 |
Goldman Sachs
New York
|
+$7.49M |
| 4 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$4.17M |
| 5 |
Jane Street
New York
|
+$3.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
-$22.4M |
| 2 |
BlackRock
New York
|
-$4.42M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$1.57M |
| 4 |
FAM
Foundation Asset Management
White Plains,
New York
|
-$906K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$846K |
TBPH Hedge Fund Activity: Q1 2018 in Review
90 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q1 2018, worth a combined $1.16B — down 12% from $1.31B a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new TBPH positions and 7 closed out — a net gain of 7 holders — while 33 added to existing stakes and 26 trimmed.
The largest buyer was Cormorant Asset Management, adding an estimated $11M. The largest seller was First Manhattan, cutting an estimated $22.4M.
- 90 institutional investors held Theravance Biopharma (TBPH) as of Q1 2018, up from 84 in Q4 2017.
- Funds reported $1.16B of Theravance Biopharma stock for Q1 2018, down 12% quarter-over-quarter.
- 14 funds opened new Theravance Biopharma positions in Q1 2018 and 7 closed out, a net change of +7 holders.
- The largest Theravance Biopharma buyer in Q1 2018 was Cormorant Asset Management, an estimated $11M added.
- The largest Theravance Biopharma seller in Q1 2018 was First Manhattan, an estimated $22.4M sold.
Based on aggregated 13F filings for Q1 2018.